Genome-wide associations identify novel candidate loci associated with genetic susceptibility to tuberculosis in wild boar.
João QueirósPaulo Célio AlvesJoaquín VicenteChristian GortázarJosé de la FuentePublished in: Scientific reports (2018)
Tuberculosis (TB) affects a wide range of host species worldwide. Understanding host-pathogen co-evolution remains a global challenge owing to complex interactions among host genetic factors, pathogen traits and environmental conditions. We used an endemic wild boar population that had undergone a huge increase in Mycobacterium bovis infection prevalence, from 45% in 2002/06 to 83% in 2009/12, to understand the effects of host genetics on host TB outcomes and disease dynamics. Host genomic variation was characterized using a high-density single nucleotide polymorphism (SNP) array, while host TB phenotype was assessed using both gross pathology and mycobacterial culture. Two complementary genome-wide association (GWAS) analyses were conducted: (i) infected-uninfected; and (ii) 2002/06-2009/12. The SNPs with the highest allelic frequency differences between time-periods and TB outcomes were identified and validated in a large dataset. In addition, we quantified the expression levels of some of their closest genes. These analyses highlighted various SNPs (i.e. rs81465339, rs81394585, rs81423166) and some of the closest genes (i.e. LOC102164072, BDNF/NT-3, NTRK2, CDH8, IGSF21) as candidates for host genetic susceptibility. In addition to TB-driven selection, our findings outline the putative role of demographic events in shaping genomic variation in natural populations and how population crashes and drift may impact host genetic susceptibility to TB over time.
Keyphrases
- genome wide
- mycobacterium tuberculosis
- dna methylation
- copy number
- high density
- genome wide association
- type diabetes
- high throughput
- high resolution
- adipose tissue
- risk factors
- single cell
- long non coding rna
- skeletal muscle
- risk assessment
- hiv infected
- hepatitis c virus
- human health
- antiretroviral therapy
- glycemic control
- adverse drug